期刊
ALZHEIMERS & DEMENTIA
卷 14, 期 11, 页码 1387-1396出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jalz.2018.05.013
关键词
Amyloid imaging; Positron emission tomography; Florbetapir; Clinical trial; Anti-amyloid; Mild cognitive impairment; Alzheimer's disease
资金
- Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
- DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
- National Institute on Aging
- National Institute of Biomedical Imaging and Bioengineering
- AbbVie
- Alzheimer's Drug Discovery Foundation
- Araclon Biotech
- Biogen
- Bristol-Myers Squibb Company
- CereSpir, Inc.
- Eisai Inc.
- Elan Pharmaceuticals, Inc.
- Eli Lilly and Company
- EuroImmun
- F. Hoffmann-La Roche Ltd
- Fujirebio
- Johnson & Johnson Pharmaceutical Research & Development LLC.
- Meso Scale Diagnostics, LLC.
- NeuroRx Research
- Novartis Pharmaceuticals Corporation
- Pfizer Inc.
- Piramal Imaging
- Takeda Pharmaceutical Company
- Canadian Institutes of Health Research
- Alzheimer Forschung Initiative e.V. (AFI)
- BioClinica, Inc.
- Janssen Alzheimer Immunotherapy Research & Development, LLC.
- Lumosity
- Lundbeck
- Merck Co., Inc.
- Neurotrack Technologies
- Servier
- Transition Therapeutics
- Genentech, Inc.
- Alzheimer's Association
- GE Healthcare
- IXICO Ltd.
Introduction: This study examined a longitudinal trajectory of beta-amyloid (A beta) accumulation at the predementia stage of Alzheimer's disease in the context of clinical trials. Methods: Analyzed were baseline (BL) and 2 years' follow-up 18F-florbetapir positron emission tomography data of 246 A beta-positive subjects with normal cognition and mild cognitive impairment. We studied the relationship between annual accumulation rates of 18F-florbetapir and BL standard uptake value ratios in whole gray matter (SUVR GM). Results: Subjects with BL SUVRGM of 0.56 to 0.92 (n = 134) appeared to accumulate A beta approximately 1.5 times faster than remaining subjects. In subjects with SUVRGM above 0.95, most regions with the highest annual accumulation rate were outside the established set of Alzheimer's disease typical regions. Conclusion: There are global and regional variations in annual accumulation rate at the predementia stage of Alzheimer's disease. When taken into account, the sample size in anti-amyloid trials can be substantially reduced. Critically, treated and placebo groups should be matched for BL SUVRGM. (C) 2018 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据